IP Library Granted Patent US 7,186,879
Granted Patent B2
US 7,186,879 · App. 10/268,822 · Granted Mar 6, 2007

Screening systems and methods for identifying modulators of xenobiotic metabolism

Assignee: Baylor College of Medicine
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,186,879
App. No.
10/268,822
Granted
Mar 6, 2007
Kind
B2
Abstract

The present invention provides mice having reduced CAR receptor activity and mice expressing a human CAR receptor. These mice are useful in screening methods to identify CAR ligands, including compounds that modulate CAR receptor activity, compounds likely to have CAR-mediated toxicity, and analogs of these compounds with less potential toxicity.

Claims (14)

1. A transgenic mouse whose genome comprises a transgene comprising a nucleic acid sequence encoding a human CAR receptor of SEQ ID NO: 2 or a functional variant thereof having at least about 95% sequence identity to SEQ ID NO: 2 operably linked to a promoter, wherein expression of said nucleic acid sequence results in the production of a human CAR receptor in the liver of said mouse, wherein the human CAR receptor induces expression of a CAR target gene.

2. The transgenic mouse of claim 1 , wherein the genome of said mouse comprises a disruption of the endogenous mouse CAR receptor gene, wherein said mouse lacks production of functional endogenous mouse CAR receptor.

3. The transgenic mouse of claim 1 , wherein said CAR target gene is CYP2B10 or CYP2B6.

4. The transgenic mouse of claim 1 , wherein said CAR target gene is CYP2B10.

5. The transgenic mouse of claim 1 , wherein said CAR target gene is CYP3A11 or CYP3A4.

6. The transgenic mouse of claim 1 , wherein said human CAR receptor is contacted with acetaminophen.

7. The transgenic mouse of claim 1 , wherein said transgene further comprises a bovine growth hormone polyadenylation sequence.

8. The transgenic mouse of claim 1 , wherein said transgene further comprises an intronic sequence of a rabbit β-globin gene.

9. The transgenic mouse of claim 8 , wherein said intronic sequence is capable of increasing the expression of said human CAR receptor.

10. The transgenic mouse of claim 1 , wherein said transgenic mouse exhibits an induction of a xenobiotic response in the presence of a xenobiotic inducer.

11. The transgenic mouse of claim 10 , wherein the xenobiotic response induces or activates of the CAR target gene.

12. The mouse of claim 11 , wherein said CAR target gene is CYP2B10.

13. The transgenic mouse of claim 11 , wherein said xenobiotic inducer is phenobarbitol.

14. The transgenic mouse of claim 10 , wherein the genome of said mouse comprises a disruption of the endogenous mouse CAR receptor gene, wherein said mouse lacks production of a functional endogenous mouse CAR receptor.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jan 29, 2015
From: BAYLOR COLLEGE OF MEDICINE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 034842/0585 →
CONFIRMATORY LICENSE Recorded Oct 2, 2014
From: BAYLOR COLLEGE OF MEDICINE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 033886/0286 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2003
From: MOORE, DAVID D.; WEI, PING; CHUA, STEVEN S.
To: BAYLOR COLLEGE OF MEDICINE
Reel/Frame 013787/0917 →
Continuity (3)
Continuation In Part 1021959000 · Aug 15, 2002
Continuation In Part PCTUS012967200 · Sep 21, 2001
Related Publication 20030150004A1 · Aug 7, 2003